Novo Nordisk Pictures

Novo Nordisk Is Falling. A Rival Weight-Loss Drug Is on Way.

Data on new Novo Nordisk obesity drug disappoints in trial, shares drop

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.

Fox Business on MSN · 2d

Novo Nordisk shares fall on weight-loss drug trial

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

Investopedia on MSN · 18h

Roche Targets Weight-Loss Drug Market Dominated by Novo Nordisk, Eli Lilly

Key Takeaways Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly.The Swiss pharmaceutical firm signed an exclusive agreement with Zealand Pharma to produce treatments using Zealand's experimental petrelintide injectable.

New York Post7d

Novo Nordisk slashing price of Wegovy to $499 a month to uninsured following rival’s move

Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to patients paying cash, as it grapples with shifts to the competitive ...

NBC Washington3d

Novo Nordisk shares fall 6.3% after latest trial results for its next-generation weight loss drug

Novo Nordisk, which manufactures the fiercely popular weight-loss drug Wegovy, previously forecast weight loss of 25% for patients who take CagriSema. In another late-trial result published in ...

U.S. News & World Report7d

Novo Nordisk Cuts Wegovy Prices, Following Similar Move by Zepbound-Maker Eli Lilly

Novo Nordisk Cuts Wegovy Prices, Following Similar Move by Zepbound-Maker Eli Lilly Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance.

USA Today7d

Wegovy price cut: Novo Nordisk cuts the price of the weight-loss drug for the uninsured

Novo Nordisk is cutting the price of its weight-loss drug Wegovy to $499 per month for cash-paying customers who buy through its NovoCare Pharmacy. The discounted price is aimed at uninsured ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results